Combination of anti-PD-L1 and radiotherapy in hepatocellular carcinoma: a mathematical model with uncertain parameters

被引:1
|
作者
Shafiekhani, Sajad [1 ]
Gheibi, Nematollah [2 ,3 ]
Esfahani, Azam Janati [2 ,3 ,4 ]
机构
[1] Smart Univ Med Sci, Artificial Intelligence Dept, Tehran, Iran
[2] Qazvin Univ Med Sci, Res Inst Prevent Noncommunicable Dis, Cellular & Mol Res Ctr, Qazvin, Iran
[3] Qazvin Univ Med Sci, Sch Paramed Sci, Dept Med Biotechnol, Qazvin, Iran
[4] Qazvin Univ Med Sci, Dept Med Biotechnol, Shahid Bahonar Blvd, Qazvin 3419915315, Iran
关键词
Hepatocellular carcinoma; anti-PD-L1; radiotherapy; in silico; ordinary differential equations; fuzzy theorem; CHECKPOINT BLOCKADE; RADIATION; IMMUNOTHERAPY; MECHANISMS;
D O I
10.1177/00375497221133846
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Blockade of programmed death-ligand-1 (PD-L1) as a new method of immunotherapy for cancers has shown limited efficacy in hepatocellular carcinoma (HCC). The combination of anti-PD-L1 and radiotherapy (RT) enhances the antitumor effect in HCC cancer. The efficacy and interactions of these treatments can be addressed by a mathematical model. We developed a mathematical model using a set of ordinary differential equations (ODEs). The variables include cancer cells, cytotoxic T lymphocytes (CTLs), programmed cell death-1 (PD-1), PD-L1, anti-PD-L1, and ionizing radiation. The model is parameterized with imprecise data set of murine HCC model and the effect of parametric uncertainty is assessed by the fuzzy theorem. The global sensitivity analysis (GSA) is performed to assess model robustness against perturbation in parameters and to identify the most influential parameters on the dynamics of cells and proteins. In silico predictions are consistent with experimental data. The model simulation shows that anti-PD-L1 and RT have a synergistic effect. In silico assessment of treatments' efficacy in the fuzzy setting of parameters revealed that anti-PD-L1 therapy, RT, and combination treatment caused the uncertainty band of tumor cells to lead to lower populations. This model as a validated rigorous simulation framework can be used to deepen our understanding of tumor and immune cell interactions and helps clinicians to investigate the efficacy of different time schedules of anti-PD-L1, RT, and combination therapy. The fuzzy theorem in conjunction with the classical ODE model that is parameterized by imprecise data was used to predict reliable outcomes of treatment.
引用
收藏
页码:313 / 325
页数:13
相关论文
共 50 条
  • [31] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
    Kudo, Masatoshi
    LIVER CANCER, 2019, 8 (06) : 413 - 426
  • [32] Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma
    Netto, George J.
    LANCET, 2016, 387 (10031): : 1881 - 1882
  • [33] Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma
    Liang, Jiahua
    Ma, Mingjian
    Feng, Wei
    Xu, Qiongcong
    Chen, Dong
    Lai, Jiaming
    Chen, Jiancong
    APOPTOSIS, 2025, 30 (1-2) : 55 - 68
  • [34] Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors
    Hernandez-Prat, Anna
    Rodriguez-Vida, Alejo
    Cardona, Laura
    Qin, Mengjuan
    Arpi-Llucia, Oriol
    Soria-Jimenez, Luis
    Menendez, Silvia
    Quimis, Fabricio Gerel
    Galindo, Miguel
    Arriola, Edurne
    Salido, Marta
    Juanpere-Rodero, Nuria
    Rojo, Federico
    Muntasell, Aura
    Albanell, Joan
    Rovira, Ana
    Bellmunt, Joaquim
    MOLECULAR ONCOLOGY, 2025, 19 (01) : 151 - 172
  • [35] Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
    Faiena, Izak
    Cummings, Amy L.
    Crosetti, Anna M.
    Pantuck, Allan J.
    Chamie, Karim
    Drakaki, Alexandra
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 209 - 215
  • [36] Soluble Programmed Death-Ligand 1 (sPD-L1) as a Novel Biomarker for the Combination of Anti-PD-L1 Antibody and Radiotherapy for Glioma Patients
    Ding, X.
    Zhou, Z.
    Ge, Z.
    Guo, Y.
    Chen, Y.
    Nie, S.
    Yu, J.
    Hu, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E588 - E588
  • [37] Combination of anti-PD-1/anti-PD-L1 Antibodies Promotes Tumor Cell Phagocytosis By Bone Marrow Derived Dcs In A Murine Neuroblastoma Model
    Inoue, S.
    Horiuchi, Y.
    Takeuchi, Y.
    Murakami, T.
    Odaka, A.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S218 - S219
  • [38] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [39] The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
    Tunger, Antje
    Sommer, Ulrich
    Wehner, Rebekka
    Kubasch, Anne Sophie
    Grimm, Marc-Oliver
    Bachmann, Michael Philipp
    Platzbecker, Uwe
    Bornhaeuser, Martin
    Baretton, Gustavo
    Schmitz, Marc
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [40] Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma
    Rui-Jun Zhang
    Hong-Mei Zhou
    Hai-Yan Lu
    Hong-Ping Yu
    Wei-Zhong Tang
    Mo-Qin Qiu
    Liu-Ying Yan
    Mei-Ying Long
    Ting-Shi Su
    Bang-De Xiang
    Mei-Ling He
    Xiao-Ting Wang
    Shi-Xiong Liang
    Jian-Xu Li
    Radiation Oncology, 18